| pubmed-article:18950467 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18950467 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:18950467 | lifeskim:mentions | umls-concept:C1708335 | lld:lifeskim |
| pubmed-article:18950467 | lifeskim:mentions | umls-concept:C0370231 | lld:lifeskim |
| pubmed-article:18950467 | lifeskim:mentions | umls-concept:C0302148 | lld:lifeskim |
| pubmed-article:18950467 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:18950467 | lifeskim:mentions | umls-concept:C0534191 | lld:lifeskim |
| pubmed-article:18950467 | lifeskim:mentions | umls-concept:C0443199 | lld:lifeskim |
| pubmed-article:18950467 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:18950467 | pubmed:dateCreated | 2008-11-10 | lld:pubmed |
| pubmed-article:18950467 | pubmed:abstractText | The haemostatic effect of recombinant activated factor VII (rFVIIa;NovoSeven) in thrombocytopenic patients has been a matter of controversy. Haemostasis by rFVIIa occurs via FVIIa-mediated thrombin generation in a platelet-dependent manner and may therefore be suboptimal in patients without functional platelets. Under such conditions, a clot-stabilizing agent, such as factor XIII (FXIII), may supplement the effect ofrFVIIa and improve haemostasis. Recombinant factor XIII (rFXIII-A2) is produced as an A2 homodimer of the FXIII A subunit and is equivalent to cellular FXIII normally found in platelets. The combined effects of rFVIIa andrFXIII-A2 were evaluated in clot lysis assays using factor XIII-deficient plasma and by whole blood thrombelastography (TEG) analysis from normal donors and thrombocytopenic stem cell transplantation patients. Clotting time was shortened by rFVIIa (0.6-10 microg/ml). rFVIIa only modestly improved anti-fibrinolysis,whereas rFXIII-A2 (0-20 microg/ml) enhanced anti-fibrinolysis without effect on clotting time. TEG analysis showed rFVIIa shortened the clotting time, and enhanced clot development, maximal mechanical strength and resistance to fibrinolysis, whereas, rFXIII-A2 enhanced clot development,maximal mechanical strength and markedly enhanced resistance to fibrinolysis. These data illustrate that rFVIIa and rFXIII-A2 contribute to clot formation and stability by different mechanisms suggesting enhanced haemostatic efficacy by combining these agents. | lld:pubmed |
| pubmed-article:18950467 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18950467 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18950467 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18950467 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18950467 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18950467 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18950467 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18950467 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18950467 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:18950467 | pubmed:issn | 1365-2141 | lld:pubmed |
| pubmed-article:18950467 | pubmed:author | pubmed-author:ViuffDortheD | lld:pubmed |
| pubmed-article:18950467 | pubmed:author | pubmed-author:PetersenLars... | lld:pubmed |
| pubmed-article:18950467 | pubmed:author | pubmed-author:AndersenSøren... | lld:pubmed |
| pubmed-article:18950467 | pubmed:author | pubmed-author:OlsenEva H... | lld:pubmed |
| pubmed-article:18950467 | pubmed:author | pubmed-author:RojkjaerRasmu... | lld:pubmed |
| pubmed-article:18950467 | pubmed:author | pubmed-author:JacobsenNiels... | lld:pubmed |
| pubmed-article:18950467 | pubmed:author | pubmed-author:JohanssonPär... | lld:pubmed |
| pubmed-article:18950467 | pubmed:author | pubmed-author:KjalkeMariann... | lld:pubmed |
| pubmed-article:18950467 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18950467 | pubmed:volume | 143 | lld:pubmed |
| pubmed-article:18950467 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18950467 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18950467 | pubmed:pagination | 559-69 | lld:pubmed |
| pubmed-article:18950467 | pubmed:meshHeading | pubmed-meshheading:18950467... | lld:pubmed |
| pubmed-article:18950467 | pubmed:meshHeading | pubmed-meshheading:18950467... | lld:pubmed |
| pubmed-article:18950467 | pubmed:meshHeading | pubmed-meshheading:18950467... | lld:pubmed |
| pubmed-article:18950467 | pubmed:meshHeading | pubmed-meshheading:18950467... | lld:pubmed |
| pubmed-article:18950467 | pubmed:meshHeading | pubmed-meshheading:18950467... | lld:pubmed |
| pubmed-article:18950467 | pubmed:meshHeading | pubmed-meshheading:18950467... | lld:pubmed |
| pubmed-article:18950467 | pubmed:meshHeading | pubmed-meshheading:18950467... | lld:pubmed |
| pubmed-article:18950467 | pubmed:meshHeading | pubmed-meshheading:18950467... | lld:pubmed |
| pubmed-article:18950467 | pubmed:meshHeading | pubmed-meshheading:18950467... | lld:pubmed |
| pubmed-article:18950467 | pubmed:meshHeading | pubmed-meshheading:18950467... | lld:pubmed |
| pubmed-article:18950467 | pubmed:meshHeading | pubmed-meshheading:18950467... | lld:pubmed |
| pubmed-article:18950467 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18950467 | pubmed:articleTitle | Differential clot stabilising effects of rFVIIa and rFXIII-A2 in whole blood from thrombocytopenic patients and healthy volunteers. | lld:pubmed |
| pubmed-article:18950467 | pubmed:affiliation | Department of Clinical Immunology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. per.johansson@rh.hosp.dk | lld:pubmed |
| pubmed-article:18950467 | pubmed:publicationType | Journal Article | lld:pubmed |
